ライフサイエンスコーパス: polycystic ovary syndrome

1 une disorders (type 2 diabetes, obesity, and polycystic ovary syndrome).

2 associated with infertile conditions such as polycystic ovary syndrome.

3 ix to eight weeks in 44 obese women with the polycystic ovary syndrome.

4 ostic decisions and treating infertility and polycystic ovary syndrome.

5 daily for 35 days in 61 obese women with the polycystic ovary syndrome.

6 genaemia which is a common characteristic of polycystic ovary syndrome.

7 ur to eight weeks in 24 obese women with the polycystic ovary syndrome.

8 0c17 alpha activity are both features of the polycystic ovary syndrome.

9 py, infertility treatment, endometriosis, or polycystic ovary syndrome.

10 mmon health conditions, such as diabetes and polycystic ovary syndrome.

11 iagnoses; 70% of women with anovulation have polycystic ovary syndrome.

12 ess disorder, insomnia, age at menarche, and polycystic ovary syndrome.

13 a gut microbiota-derived metabolite induces polycystic ovary syndrome.

14 troke, nonalcoholic fatty liver disease, and polycystic ovary syndrome.

15 and quality of life of infertile women with polycystic ovary syndrome.

16 ulation rates among infertile women with the polycystic ovary syndrome.

17 seen in diseases of excess androgens such as polycystic ovary syndrome.

18 lays a key role in the early pathogenesis of polycystic ovary syndrome.

19 ND1A) previously shown to be associated with polycystic ovary syndrome.

20 of adolescents are presenting with signs of polycystic ovary syndrome.

21 enital adrenal hyperplasia often develop the polycystic ovary syndrome.

22 narche and hyperandrogenic disorders such as polycystic ovary syndrome.

23 serum androgen concentrations in women with polycystic ovary syndrome.

24 Polycystic ovary syndrome, a fertility disorder affectin

25 nd is elevated in women with androgen excess polycystic ovary syndrome (AE-PCOS).

26 eving live birth in infertile women with the polycystic ovary syndrome, although multiple birth is a

27 ppearing more frequently in type 2 diabetic, polycystic ovary syndrome and CHD cases.

28 Naylor's valuable critique of our study "Polycystic Ovary Syndrome and Endometrial Cancer Risk: R

29 2-1.16; P = 0.007); and genetic liability to polycystic ovary syndrome and endometrioid carcinoma (OR

30 ences in vaginal microbiota between cases of polycystic ovary syndrome and healthy controls.

31 disrupted in pathological conditions such as polycystic ovary syndrome and hypothalamic amenorrhea.

32 In patients with polycystic ovary syndrome and insulin resistance, piogli

33 veral phenotypes, including type 1 diabetes, polycystic ovary syndrome, and birth weight.

34 g obesity, type 2 diabetes, hepatitis C, and polycystic ovary syndrome, and is a primary feature of m

35 a) improves ovulatory function in women with polycystic ovary syndrome, and specific dietary fatty ac

36 ecological conditions-such as endometriosis, polycystic ovary syndrome, and uterine fibroids-have rem

37 pecially primary ovarian insufficiency), and polycystic ovary syndrome are also relevant, with good e

38 Obese women with the polycystic ovary syndrome are relatively unresponsive to

39 drenal hyperplasia, premature adrenarche and polycystic ovary syndrome, as well as in androgen-depend

40 ed, in part, by PCOS Challenge: The National Polycystic Ovary Syndrome Association and by the Foundat

41 line infertility treatment in women with the polycystic ovary syndrome, but aromatase inhibitors, inc

42 ene can be increased in obese women with the polycystic ovary syndrome by decreasing insulin secretio

43 In 18 overweight women with IR and polycystic ovary syndrome compared with 12 lean control

44 In obese women with the polycystic ovary syndrome, decreasing serum insulin conc

45 of start of follow-up, parity, diagnosis of polycystic ovary syndrome, diabetes, chronic hypertensio

46 ental disorders, endometriosis, menorrhagia, polycystic ovary syndrome, dysmenorrhea, leiomyoma, and

47 diagnosis, disease duration, treatment, and polycystic ovary syndrome, endometriosis, bilateral ooph

48 56), after adjustment for education, parity, polycystic ovary syndrome, energy intake, and physical a

49 bout limitations of the test, which included polycystic ovary syndrome falsely inflating AMH levels (

50 s for the analysis of a previously described polycystic ovary syndrome gene expression dataset.

51 MI 33 kg/m(2)), insulin-resistant women with polycystic ovary syndrome had aberrant skeletal muscle m

52 The two common forms of polycystic ovary syndrome have different origins in intr

53 Women with the polycystic ovary syndrome have insulin resistance and hy

54 ease, hypertension, stroke, type 2 diabetes, polycystic ovary syndrome, heart failure, atrial fibrill

55 of underlying androgen excess, particularly polycystic ovary syndrome in women.

56 Early and late menarche, polycystic ovary syndrome, infertility, adverse pregnanc

57 The polycystic ovary syndrome is a common cause of infertili

58 Polycystic ovary syndrome is characterized by an excess

59 Polycystic ovary syndrome is estimated to affect 5-10% o

60 nce thought to affect primarily adult women, polycystic ovary syndrome is frequently diagnosed during

61 Polycystic ovary syndrome is one of the commonest and co

62 Polycystic ovary syndrome is the most common cause of an

63 an overview of our current understanding of polycystic ovary syndrome, its epidemiology and natural

64 the University of California, San Francisco, Polycystic Ovary Syndrome Multidisciplinary Clinic over

65 genes associated with spontaneous abortion, polycystic ovary syndrome, myocardial infarction and mel

66 ively due to its associations with diabetes, polycystic ovary syndrome, obesity and birth size.

67 onfidence interval (95% CI): 1.22-1.53)) and polycystic ovary syndrome (OR = 1.51 (95% CI: 1.33-1.72)

68 sed overwhelmingly on affective disorders in polycystic ovary syndrome, overlooking a substantial por

69 eptibility loci that are associated with the polycystic ovary syndrome (PCOS) affection status by scr

70 Polycystic ovary syndrome (PCOS) affects 5% of reproduct

71 Correlates of diagnosed and probable polycystic ovary syndrome (PCOS) among parous women were

72 tatic model assessment [HOMA]) in women with polycystic ovary syndrome (PCOS) and chronic periodontit

73 y and densitometry features in patients with polycystic ovary syndrome (PCOS) and compare them with h

74 terleukin-6 (IL-6) in non-obese females with polycystic ovary syndrome (PCOS) and either clinically h

75 he understanding of the relationship between polycystic ovary syndrome (PCOS) and endometrial cancer

76 red in common reproductive disorders such as polycystic ovary syndrome (PCOS) and hypothalamic amenor

77 tor of MMP-1 (TIMP)-1 ratio in patients with polycystic ovary syndrome (PCOS) and systemically health

78 Pregnant women with polycystic ovary syndrome (PCOS) are often overweight or

79 Early age at menarche (early AAM) and polycystic ovary syndrome (PCOS) are reproductive and me

80 teristics differed in women with and without polycystic ovary syndrome (PCOS) between a Caucasian and

81 As a heterogeneous reproductive disorder, polycystic ovary syndrome (PCOS) can be caused by geneti

82 Women with polycystic ovary syndrome (PCOS) commonly suffer from mi

83 Women with polycystic ovary syndrome (PCOS) commonly suffer from mi

84 EPS) are altered in myotubes from women with polycystic ovary syndrome (PCOS) compared to healthy con

85 Ms R, a 27-year-old woman with polycystic ovary syndrome (PCOS) diagnosed after irregul

86 Women with polycystic ovary syndrome (PCOS) exhibit elevated androg

87 Women with polycystic ovary syndrome (PCOS) frequently experience d

88 Polycystic ovary syndrome (PCOS) has been associated wit

89 ars, it has been clearly documented that the polycystic ovary syndrome (PCOS) has major metabolic seq

90 Women with polycystic ovary syndrome (PCOS) have been shown to be l

91 female first-degree relatives of women with polycystic ovary syndrome (PCOS) have hyperandrogenemia

92 Approximately 70% of women with polycystic ovary syndrome (PCOS) have intrinsic insulin

93 an morphologic measurements for diagnosis of polycystic ovary syndrome (PCOS) in adolescents.

94 or metformin for comprehensive management of polycystic ovary syndrome (PCOS) in women with obesity i

95 Polycystic ovary syndrome (PCOS) is a common and heterog

96 Polycystic ovary syndrome (PCOS) is a common endocrine d

97 Polycystic ovary syndrome (PCOS) is a common endocrine d

98 Polycystic ovary syndrome (PCOS) is a common endocrine d

99 Polycystic ovary syndrome (PCOS) is a common problem amo

100 Polycystic ovary syndrome (PCOS) is a common, complex ge

101 Polycystic ovary syndrome (PCOS) is a common, highly her

102 Polycystic ovary syndrome (PCOS) is a complex hormonal d

103 Polycystic ovary syndrome (PCOS) is a complex syndrome w

104 Polycystic ovary syndrome (PCOS) is a heterogeneous cond

105 Polycystic ovary syndrome (PCOS) is a heterogenous disor

106 Polycystic ovary syndrome (PCOS) is a hypothalamic-pitui

107 Polycystic ovary syndrome (PCOS) is a leading cause of a

108 Polycystic ovary syndrome (PCOS) is a major reproductive

109 Polycystic ovary syndrome (PCOS) is a multifactorial dis

110 Polycystic ovary syndrome (PCOS) is a prevalent endocrin

111 Polycystic ovary syndrome (PCOS) is a prevalent endocrin

112 Polycystic ovary syndrome (PCOS) is a prevalent endocrin

113 Despite affecting ~11-13% of women globally, polycystic ovary syndrome (PCOS) is a substantially unde

114 Polycystic ovary syndrome (PCOS) is among the most commo

115 The polycystic ovary syndrome (PCOS) is an extremely common

116 Polycystic ovary syndrome (PCOS) is associated with card

117 Polycystic ovary syndrome (PCOS) is associated with insu

118 Polycystic ovary syndrome (PCOS) is associated with symp

119 Polycystic ovary syndrome (PCOS) is associated with the

120 Use of metformin in polycystic ovary syndrome (PCOS) is becoming increasingl

121 Polycystic ovary syndrome (PCOS) is characterised by a h

122 Polycystic ovary syndrome (PCOS) is characterized by and

123 Polycystic ovary syndrome (PCOS) is common in women of r

124 Polycystic ovary syndrome (PCOS) is frequently associate

125 nostic criteria in women suspected of having polycystic ovary syndrome (PCOS) is incomplete.

126 Polycystic ovary syndrome (PCOS) is the most common caus

127 Polycystic ovary syndrome (PCOS) is the most common endo

128 Polycystic ovary syndrome (PCOS) is the most common endo

129 Polycystic ovary syndrome (PCOS) is the most common horm

130 Polycystic ovary syndrome (PCOS) is the most common repr

131 ly, some studies have revealed the effect of polycystic ovary syndrome (PCOS) on gingival inflammatio

132 Polycystic ovary syndrome (PCOS) recently has been ident

133 Insulin resistance in polycystic ovary syndrome (PCOS) results from a postbind

134 women in their reproductive age suffer from polycystic ovary syndrome (PCOS) that, alongside subfert

135 ations in B cell numbers are associated with polycystic ovary syndrome (PCOS) through unknown mechani

136 arous women with diagnosed, probable, and no polycystic ovary syndrome (PCOS) throughout 15-year foll

137 The prevalence of polycystic ovary syndrome (PCOS) varies across the globe

138 hyperandrogenic insulin-resistant women with polycystic ovary syndrome (PCOS) who are at increased ri

139 Polycystic ovary syndrome (PCOS) women have a hypercoagu

140 d androgen excess with insulin resistance in polycystic ovary syndrome (PCOS) women.

141 Using an ovine model of polycystic ovary syndrome (PCOS), (pregnant ewes injecte

142 Maternal polycystic ovary syndrome (PCOS), a common metabolic dis

143 This would suggest that maternal polycystic ovary syndrome (PCOS), a condition associated

144 ent study, we evaluate a group of women with polycystic ovary syndrome (PCOS), a condition characteri

145 n to this model because it is usually due to polycystic ovary syndrome (PCOS), a condition in which i

146 nd stroma are also prominent features of the polycystic ovary syndrome (PCOS), a leading cause of inf

147 These include polycystic ovary syndrome (PCOS), abnormal uterine bleed

148 orioretinopathy (CSCR) among transmasculine, polycystic ovary syndrome (PCOS), and androgen-exposed p

149 Endothelin-1 is elevated in women with polycystic ovary syndrome (PCOS), and may play a role in

150 alleles are associated with type 2 diabetes, polycystic ovary syndrome (PCOS), and size at birth.

151 g bacterial vaginosis, gestational diabetes, polycystic ovary syndrome (PCOS), anxiety, depression, a

152 Dyslipidemia is a feature of polycystic ovary syndrome (PCOS), but its pathogenesis r

153 Girls with T2D are at risk of developing polycystic ovary syndrome (PCOS), but the prevalence of

154 Polycystic ovary syndrome (PCOS), characterized by incre

155 Polycystic ovary syndrome (PCOS), characterized by irreg

156 ment parameters across various phenotypes of polycystic ovary syndrome (PCOS), considering body mass

157 ty, and hirsutism, common characteristics of polycystic ovary syndrome (PCOS), improve with even mode

158 iome and chronic metabolic disease including polycystic ovary syndrome (PCOS), is well documented, ho

159 similar to those displayed in patients with polycystic ovary syndrome (PCOS), such as follicular gro

160 oxidative stress, in the pathophysiology of polycystic ovary syndrome (PCOS), the most common endocr

161 upport faster and more accurate diagnosis of polycystic ovary syndrome (PCOS), with a focus on both p

162 resents a significant concern for women with polycystic ovary syndrome (PCOS), with deleterious psych

163 thesis and/or metabolism in the aetiology of polycystic ovary syndrome (PCOS).

164 rexposure associated with conditions such as polycystic ovary syndrome (PCOS).

165 neuropathy, ketoacidosis, hypothyroidism and polycystic ovary syndrome (PCOS).

166 inical atherosclerotic markers in women with polycystic ovary syndrome (PCOS).

167 nt for preventing and treating patients with polycystic ovary syndrome (PCOS).

168 risk of endometrial cancer among women with polycystic ovary syndrome (PCOS).

169 cose homeostasis and hormone levels in women polycystic ovary syndrome (PCOS).

170 ciated with insulin resistance in women with polycystic ovary syndrome (PCOS).

171 levels correlate with increased severity of polycystic ovary syndrome (PCOS).

172 yperandrogenism are the cardinal features of polycystic ovary syndrome (PCOS).

173 s increasing evidence of their importance in polycystic ovary syndrome (PCOS).

174 fertility and thus serve as a model of human polycystic ovary syndrome (PCOS).

175 has metabolic advantages in the treatment of polycystic ovary syndrome (PCOS).

176 to the concentrations that can occur during polycystic ovary syndrome (PCOS).

177 An association between polycystic ovary syndrome (PCOS)and endometrial carcinom

178 of healthy women (n = 9), and in women with polycystic ovary syndrome (PCOS; n = 6) or hypothalamic

179 d androgen excess and a phenotype resembling polycystic ovary syndrome (PCOS; refs. 1,2).

180 eted educational qualification, nulliparity, polycystic ovary syndrome, physical activity, and body m

181 ideline for the Assessment and Management of Polycystic Ovary Syndrome, requiring two out of three cr

182 Polycystic ovary syndrome's (PCOS) main feature is hyper

183 rched PubMed using a string of variations of polycystic ovary syndrome, therapy/treatment, and adoles

184 s the action of insulin in patients with the polycystic ovary syndrome, thereby improving ovulatory f

185 ndomly assigned 626 infertile women with the polycystic ovary syndrome to receive clomiphene citrate

186 nificant benefit when including metformin in polycystic ovary syndrome treatment regimens.

187 netic liability to 3 factors (endometriosis, polycystic ovary syndrome, type 2 diabetes) scaled to re

188 evels, that they hypothesized could point to polycystic ovary syndrome underpinning these association

189 sex hormone-dependent cancers and diseases (polycystic ovary syndrome, uterine fibroids, endometrios

190 s described in the literature and found that polycystic ovary syndrome was associated with increased

191 The polycystic ovary syndrome was defined according to modif

192 enetically correlated with endometriosis and polycystic ovary syndrome, we find limited genetic overl

193 ulin resistance is observed in patients with polycystic ovary syndrome, we hypothesized that TAC or S

194 ed controlled trial, 60 infertile women with polycystic ovary syndrome were randomly selected and ass

195 proate, is associated with the occurrence of polycystic ovary syndrome when used in young adulthood o

196 ons, linking dementia with bone development, polycystic ovary syndrome with cardiovascular developmen